Terms: = Germ cell tumor AND MAX, MGC36767, 4149, ENSG00000125952, MGC18164, MGC10775, P61244, MGC11225, orf1, MGC34679 AND Prognosis
75 results:
1. Protoporphyrin IX in serum of high-grade glioma patients: A novel target for disease monitoring via liquid biopsy.
Walke A; Krone C; Stummer W; König S; Suero Molina E
Sci Rep; 2024 Feb; 14(1):4297. PubMed ID: 38383693
[TBL] [Abstract] [Full Text] [Related]
2. Updates on the genetics of multiple endocrine neoplasia.
Sahakian N; Castinetti F; Romanet P; Reznik Y; Brue T
Ann Endocrinol (Paris); 2024 Apr; 85(2):127-135. PubMed ID: 38325596
[TBL] [Abstract] [Full Text] [Related]
3. PSMA PET/MR is a New Imaging Option for Identifying Glioma Recurrence and Predicting prognosis.
Xiong M; Chen Z; Zhou C; Yang X; Hu W; Jiang Y; Zheng R; Fan W; Mou Y; Lin X
Recent Pat Anticancer Drug Discov; 2024; 19(3):383-395. PubMed ID: 38214322
[TBL] [Abstract] [Full Text] [Related]
4. Individualized discrimination of tumor progression from treatment-related changes in different types of adult-type diffuse gliomas using [
Chen Q; Wang K; Ren X; Zhao X; Chen Q; Fan D; Zhang S; Li X; Ai L
J Neurooncol; 2023 Dec; 165(3):547-559. PubMed ID: 38095773
[TBL] [Abstract] [Full Text] [Related]
5. 68 Ga-PSMA-11 PET/CT Imaging in Brain Gliomas and Its Correlation With Clinicopathological Prognostic Parameters.
Verma P; Singh BK; Sudhan MD; Singh RK; Bagul SD; Chandak AR; Soni BK; Shelly D; Basu S
Clin Nucl Med; 2023 Dec; 48(12):e559-e563. PubMed ID: 37883060
[TBL] [Abstract] [Full Text] [Related]
6. High tumor Uptake on
De Rycke O; Perrier M; Ouvrard É; Mennetrey C; Lachachi C; Bando-Delaunay A; Morland D; Goichot B; Taieb D; Walter T; Cadiot G; Cros J; Hentic O; Ruszniewski P; Lebtahi R; Imperiale A; de Mestier L
J Nucl Med; 2023 Nov; 64(11):1699-1705. PubMed ID: 37652547
[TBL] [Abstract] [Full Text] [Related]
7. AI-based Virtual Synthesis of Methionine PET from Contrast-enhanced MRI: Development and External Validation Study.
Takita H; Matsumoto T; Tatekawa H; Katayama Y; Nakajo K; Uda T; Mitsuyama Y; Walston SL; Miki Y; Ueda D
Radiology; 2023 Aug; 308(2):e223016. PubMed ID: 37526545
[TBL] [Abstract] [Full Text] [Related]
8. The Myc Family and the Metastasis Suppressor NDRG1: Targeting Key Molecular Interactions with Innovative Therapeutics.
Deng Z; Richardson DR
Pharmacol Rev; 2023 Sep; 75(5):1007-1035. PubMed ID: 37280098
[TBL] [Abstract] [Full Text] [Related]
9. Neuroblastoma-derived v-myc avian myelocytomatosis viral related oncogene or
Bhardwaj N; Das G; Srinivasan R
J Clin Pathol; 2023 Aug; 76(8):518-523. PubMed ID: 37221048
[TBL] [Abstract] [Full Text] [Related]
10. Melanin-targeted [
Zhang X; Lin Z; Li M; Gai Y; Zheng H; Fan L; Ruan W; Hu F; Chen J; Lan X
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3062-3071. PubMed ID: 37191681
[TBL] [Abstract] [Full Text] [Related]
11. Prediction of Ki-67 labeling index, ATRX mutation, and MGMT promoter methylation status in IDH-mutant astrocytoma by morphological MRI, SWI, DWI, and DSC-PWI.
Yang X; Hu C; Xing Z; Lin Y; Su Y; Wang X; Cao D
Eur Radiol; 2023 Oct; 33(10):7003-7014. PubMed ID: 37133522
[TBL] [Abstract] [Full Text] [Related]
12. MYCMI-7: A Small MYC-Binding Compound that Inhibits MYC: max Interaction and tumor Growth in a MYC-Dependent Manner.
Castell A; Yan Q; Fawkner K; Bazzar W; Zhang F; Wickström M; Alzrigat M; Franco M; Krona C; Cameron DP; Dyberg C; Olsen TK; Verschut V; Schmidt L; Lim SY; Mahmoud L; Hydbring P; Lehmann S; Baranello L; Nelander S; Johnsen JI; Larsson LG
Cancer Res Commun; 2022 Mar; 2(3):182-201. PubMed ID: 36874405
[TBL] [Abstract] [Full Text] [Related]
13. An integrative non-invasive malignant brain tumors classification and Ki-67 labeling index prediction pipeline with radiomics approach.
Zhang L; Liu X; Xu X; Liu W; Jia Y; Chen W; Fu X; Li Q; Sun X; Zhang Y; Shu S; Zhang X; Xiang R; Chen H; Sun P; Geng D; Yu Z; Liu J; Wang J
Eur J Radiol; 2023 Jan; 158():110639. PubMed ID: 36463703
[TBL] [Abstract] [Full Text] [Related]
14. TSPO PET signal using [
Quach S; Holzgreve A; Kaiser L; Unterrainer M; Dekorsy FJ; Nelwan DV; Bartos LM; Kirchleitner SV; Weller J; Weidner L; Niyazi M; Ruf VC; Herms J; Stöcklein S; Wetzel C; Riemenschneider MJ; V Baumgarten L; Thon N; Brendel M; Rupprecht R; Bartenstein P; Tonn JC; Albert NL
Eur J Nucl Med Mol Imaging; 2023 Feb; 50(3):859-869. PubMed ID: 36329288
[TBL] [Abstract] [Full Text] [Related]
15. Prospective Phase II Trial of [
Carlsen EA; Loft M; Loft A; Czyzewska D; Andreassen M; Langer SW; Knigge U; Kjaer A
J Nucl Med; 2023 Feb; 64(2):252-259. PubMed ID: 35981899
[TBL] [Abstract] [Full Text] [Related]
16. Volumetric parameters from [
Langen Stokmo H; Aly M; Bowitz Lothe IM; Borja AJ; Mehdizadeh Seraj S; Ghorpade R; Miao X; Hjortland GO; Malinen E; Sorbye H; Werner TJ; Alavi A; Revheim ME
J Neuroendocrinol; 2022 Jul; 34(7):e13170. PubMed ID: 35729738
[TBL] [Abstract] [Full Text] [Related]
17. Grading of IDH-mutant astrocytoma using diffusion, susceptibility and perfusion-weighted imaging.
Yang X; Xing Z; She D; Lin Y; Zhang H; Su Y; Cao D
BMC Med Imaging; 2022 May; 22(1):105. PubMed ID: 35644621
[TBL] [Abstract] [Full Text] [Related]
18. Development of VPC-70619, a Small-Molecule N-Myc Inhibitor as a Potential Therapy for Neuroendocrine Prostate Cancer.
Ton AT; Foo J; Singh K; Lee J; Kalyta A; Morin H; Perez C; Ban F; Leblanc E; Lallous N; Cherkasov A
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269731
[TBL] [Abstract] [Full Text] [Related]
19. Prospective Phase II Trial of Prognostication by
Carlsen EA; Loft M; Loft A; Berthelsen AK; Langer SW; Knigge U; Kjaer A
J Nucl Med; 2022 Sep; 63(9):1371-1377. PubMed ID: 35058319
[TBL] [Abstract] [Full Text] [Related]
20. Dynamic susceptibility contrast-MRI parameters, ADC values, and the T2-FLAIR mismatch sign are useful to differentiate between H3-mutant and H3-wild-type high-grade midline glioma.
Kurokawa R; Kurokawa M; Baba A; Ota Y; Kim J; Capizzano A; Srinivasan A; Moritani T
Eur Radiol; 2022 Jun; 32(6):3672-3682. PubMed ID: 35022811
[TBL] [Abstract] [Full Text] [Related]
[Next]
